← Back to Clinical Trials
Unknown NCT05114330

NCT05114330 Secondary Central Nervous System Lymphoma Registry - Charité

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05114330
Status Unknown
Phase
Sponsor Charite University, Berlin, Germany
Condition Central Nervous System Lymphoma
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2011-06-08
Primary Completion 2024-06-08

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2011-06-08 with a primary completion date of 2024-06-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of the observation is to collect and document data on treatment strategies for secondary central nervous system lymphoma (SCNSL) in routine clinical practice, whether obtained in the context of clinical trials or outside of trials. In particular, the following questions will be specified: * What therapeutic approaches are being pursued? * What is the clinical outcome of the various treatment options? * What is the frequency of serious adverse events with each therapeutic approach?

Eligibility Criteria

Inclusion Criteria: • All patients with SCNSL can and should be included in the registry regardless of which treatment options are used and whether the treatment being given is first-line, recurrence, or maintenance therapy for SCNSL. Exclusion Criteria: • None

Contact & Investigator

Central Contact

Stefan Habringer, MD

✉ stefan.habringer@charite.de

Frequently Asked Questions

Who can join the NCT05114330 clinical trial?

This trial is open to participants of all sexes, studying Central Nervous System Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05114330 currently recruiting?

NCT05114330 is currently listed as "Unknown" and is not actively enrolling. Check ClinicalTrials.gov for the latest status updates.

Where is the NCT05114330 trial being conducted?

This trial is being conducted at Berlin, Germany.

Who is sponsoring the NCT05114330 clinical trial?

NCT05114330 is sponsored by Charite University, Berlin, Germany. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology